1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,780 | 4,830 | 30.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.12. | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): BUY | 239 | EQS Group (EN) | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
10.12.2025 / 11:25 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| 08.12. | MaaT Pharma reports 54% one-year survival rate in pivotal GvHD trial | 1 | Investing.com | ||
| 08.12. | MaaT Pharma meldet 54 % Ein-Jahres-Überlebensrate in zulassungsrelevanter GvHD-Studie | 3 | Investing.com Deutsch | ||
| 08.12. | MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival | 567 | Business Wire | Presentation included previously disclosed primary results from the pivotal ARES Phase 3 single-arm trial evaluating MaaT013 (Xervyteg) in treating refractory severe acute Graft-versus-Host Disease... ► Artikel lesen | |
| 19.11. | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): BUY | 253 | EQS Group (EN) | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
19.11.2025 / 11:11 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| 17.11. | XFRA 4RD: WIEDERAUFNAHME/RESUMPTION | 118 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 14.11. | MaaT Pharma Announces the Successful Completion of Its Global Offering of €9.1 Million | 402 | Business Wire | Regulatory News:
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO... ► Artikel lesen | |
| MAAT PHARMA Aktie jetzt für 0€ handeln | |||||
| 14.11. | XFRA 4RD: AUSSETZUNG/SUSPENSION | 236 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMAAT PHARMA S.A.... ► Artikel lesen | |
| 13.11. | MaaT Pharma Launches a Capital Increase of Approximately €9 Million | 498 | Business Wire | Launch of a Global Offering of new ordinary shares for approximately €9 million through a Private Placement aimed at qualified investors, and a PrimaryBid Offering aimed at retail investors via... ► Artikel lesen | |
| 05.11. | MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034 | 342 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 04.11. | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): BUY | 254 | EQS Group (EN) | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
04.11.2025 / 11:37 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| 04.11. | MaaT Pharma Reports Financial Results for the Third Quarter 2025 and Provides Financing Update | 314 | Business Wire | The Company received an upfront payment of €10.5 million in July 2025 after the signature of an exclusive license and distribution agreement with Clinigen. Subject to approval and grant of a Marketing... ► Artikel lesen | |
| 03.11. | MaaT Pharma's Xervyteg shows 62% response rate in GI-aGvHD trial | 5 | Investing.com | ||
| 03.11. | MaaT Pharma: Xervyteg erzielt 62 % Ansprechrate in entscheidender Studie zu GI-aGvHD | 4 | Investing.com Deutsch | ||
| 03.11. | MaaT Pharma Announces Positive Phase 3 Results Evaluating Xervyteg (MaaT013) in Acute Graft-versus-Host Disease Selected for Oral Presentation at ASH Congress 2025 | 320 | Business Wire | Oral presentation at ASH 2025 to feature pivotal Phase 3 results of Xervyteg (MaaT013), including previously disclosed primary endpoint data (62% GI-ORR at Day 28) and new findings on secondary... ► Artikel lesen | |
| 07.10. | MaaT Pharma stock jumps 11% after DSMB clears Phase 2b trial to continue | 6 | Investing.com | ||
| 07.10. | MaaT Pharma's MaaT033 For Allo-HSCT Patients Clears Second DSMB Safety Review In Phase 2b Trial | 2 | RTTNews | ||
| 07.10. | MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT | 319 | Business Wire | The DSMB conducted an unblinded safety review of data from the first 120 enrolled patients and identified no safety concerns and no excessive mortality related to MaaT033 as of today. The... ► Artikel lesen | |
| 17.09. | MaaT Pharma Publishes Its Half Year 2025 Results and Provides a Business Update | 501 | Business Wire | Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results showed a 62% gastrointestinal overall response rate at Day 28 and 1-year expected Overall... ► Artikel lesen | |
| 30.07. | MaaT Pharma: €37.5 Million EIB Loan Secured To Advance Cancer Therapies | 3 | pulse2.com |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 48,600 | -0,31 % | BB Biotech im Aufwind - Zinswende treibt Biotech-Rally an | US-Zinssenkung belebt den Biotech-Sektor. BB Biotech glänzt mit starkem Quartal, vier Exits und klarer Outperformance gegenüber dem Nasdaq Biotech Index. Seit der ersten Zinssenkung der US-Notenbank... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,850 | +0,56 % | Cathie Wood's ARK makes strategic stock moves, buys Intellia and sells Roku | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,459 | -1,83 % | Cathie Wood's ARK buys Weride, Pacific Biosciences stocks, sells Ibotta | ||
| MICROBOT MEDICAL | 1,828 | +1,67 % | Microbot Medical Inc.: Microbot Medical Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio | Commercial Focus Remains on U.S. Market as it Continues to Explore Certain Global Markets that Accept FDA Cleared Devices Protecting its Innovative Technology Remains a Priority and Momentum Increasing... ► Artikel lesen | |
| ATAI BECKLEY | 3,391 | +0,36 % | AtaiBeckley N.V.: AtaiBeckley Completes Redomiciliation to the United States | NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing... ► Artikel lesen | |
| BIOMERIEUX | 110,00 | -0,18 % | BIOMERIEUX: bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health | ||
| BIOXCEL THERAPEUTICS | 1,306 | -1,51 % | BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements | NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in... ► Artikel lesen | |
| CYBIN | 8,050 | +1,26 % | Biggest stock movers Wednesday: Vanda Pharmaceuticals and Cybin | ||
| BIO GREEN MED SOLUTION | 1,580 | +8,97 % | Bio Green Med Solution, Inc.: Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update | KUALA LUMPUR, Malaysia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS, NASDAQ: BGMSP; "BGMS" or the "Company" (formerly Cyclacel Pharmaceuticals, Inc.)), a diversified... ► Artikel lesen | |
| PDS BIOTECHNOLOGY | 0,710 | +1,00 % | PDS Biotechnology Corporation: PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update | Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Cancer Phase 2 Results Lead Company to Seek Expedited Approval... ► Artikel lesen | |
| GENUS | 29,400 | +0,68 % | Dividendenbekanntmachungen (06.11.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AIRTEL AFRICA PLC GB00BKDRYJ47 0,0216 GBP 0,0245 EUR ARMSTRONG WORLD INDUSTRIES INC US04247X1028 0,339 USD 0,2949 EUR ASHMORE GROUP... ► Artikel lesen | |
| ANAPTYSBIO | 43,600 | +0,46 % | GSK und AnaptysBio verklagen einander wegen angeblicher Lizenzverstöße | DJ GSK und AnaptysBio verklagen einander wegen angeblicher Lizenzverstöße
Von Elena Vardon
DOW JONES--Der Arzneimittelhersteller GSK und das US-Biotechunternehmen AnaptysBio haben einen Rechtsstreit... ► Artikel lesen | |
| ABIONYX PHARMA | 3,505 | -3,58 % | ABIONYX Pharma Carries Out a Capital Increase With Cancellation of Preferential Subscription Rights in Favor of Certain Categories of Persons, Amounting to Approximately €1.8m | Capital increase of approximately 1.8 million euros Subscription price: 3.10 euros Extension of financial visibility until the end of 2026
Regulatory News:
ABIONYX Pharma, (FR0012616852... ► Artikel lesen | |
| AKESO | 12,300 | 0,00 % | Akeso, Inc.: Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab | HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 0,525 | +1,94 % | XTL Biopharmaceuticals Ltd.: XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency | RAMAT GAN, ISRAEL, Dec. 24, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a notification letter from... ► Artikel lesen |
Das Unternehmen MAAT PHARMA SA kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,170 (+3,72 %) liegt der Kurs bei 4,740 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAAT PHARMA SA finden Sie auf Wallstreet Online.